Wells Fargo & Company Issues Pessimistic Forecast for Avantor (NYSE:AVTR) Stock Price

Avantor (NYSE:AVTR) had its price objective reduced by Wells Fargo & Company from $28.00 to $25.00 in a research note released on Monday morning,Benzinga reports. They currently have an overweight rating on the stock.

Several other analysts have also recently commented on AVTR. UBS Group restated a “neutral” rating and issued a $25.00 price target (down previously from $29.00) on shares of Avantor in a report on Friday, January 17th. Stifel Nicolaus decreased their target price on shares of Avantor from $28.00 to $26.00 and set a “buy” rating on the stock in a research report on Monday. Raymond James dropped their price target on shares of Avantor from $29.00 to $26.00 and set an “outperform” rating for the company in a research report on Tuesday, January 21st. Barclays decreased their price target on shares of Avantor from $26.00 to $23.00 and set an “overweight” rating on the stock in a report on Monday. Finally, Robert W. Baird lowered their price objective on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research note on Monday, October 28th. Three research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $26.15.

Avantor Stock Performance

Shares of AVTR opened at $19.00 on Monday. The company has a market capitalization of $12.93 billion, a price-to-earnings ratio of 41.30, a PEG ratio of 3.87 and a beta of 1.28. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.06 and a current ratio of 1.54. Avantor has a 1 year low of $18.49 and a 1 year high of $28.00. The company’s 50 day simple moving average is $21.73 and its 200 day simple moving average is $23.47.

Avantor (NYSE:AVTR) last posted its quarterly earnings data on Wednesday, February 12th. The company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.26 by $0.01. Avantor had a return on equity of 12.24% and a net margin of 4.54%. During the same quarter in the previous year, the business earned $0.22 EPS. On average, sell-side analysts predict that Avantor will post 0.98 EPS for the current year.

Hedge Funds Weigh In On Avantor

Large investors have recently modified their holdings of the stock. Louisiana State Employees Retirement System grew its position in shares of Avantor by 0.3% in the 4th quarter. Louisiana State Employees Retirement System now owns 188,900 shares of the company’s stock worth $3,980,000 after acquiring an additional 500 shares in the last quarter. Hantz Financial Services Inc. grew its position in shares of Avantor by 2.1% during the 3rd quarter. Hantz Financial Services Inc. now owns 24,900 shares of the company’s stock valued at $644,000 after buying an additional 503 shares during the last quarter. Blue Trust Inc. boosted its stake in Avantor by 6.9% in the fourth quarter. Blue Trust Inc. now owns 8,069 shares of the company’s stock valued at $170,000 after acquiring an additional 522 shares during the period. Pacer Advisors Inc. grew its holdings in shares of Avantor by 0.5% during the fourth quarter. Pacer Advisors Inc. now owns 99,825 shares of the company’s stock valued at $2,103,000 after purchasing an additional 542 shares during the last quarter. Finally, Veracity Capital LLC raised its position in shares of Avantor by 1.0% during the 3rd quarter. Veracity Capital LLC now owns 52,359 shares of the company’s stock worth $1,355,000 after purchasing an additional 543 shares during the period. Institutional investors own 95.08% of the company’s stock.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.